Beyond NASH: Genfit jumps into another Critical Liver Condition

31/03/2016 - 2 minutes

Genfit is extending the applications of its star candidate, Elafibranor, to a second liver disease – Primary Biliary Cholangitis (PBC), a rare condition with high unmet medical needs.

genfit_liver_primary_biliary_cholangitisGenfit from Lille (France) has been in the spotlight because of its phase III candidate for NASH – something we discussed with its CEO, Jean-François Mouney.

Apparently, all the hype is not making Genfit lazy. It has just announced that it will diversify the diseases targeted by Elafibranor with a new trial in primary biliary cholangitis (PBC).

PBC is a chronic disease that causes the bile ducts to become inflamed, gradually destroying them. Bile ducts are a sort of internal plumbing to carry bile (which is secreted in the liver) to the intestine, where it is essential for food digestion.

The current treatment for PBC is ursodeoxycholic acid (UDCA), which replaces bile acids. But around 70% of the patients don’t tolerate or don’t respond sufficiently to this therapy –

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member